Seasonal influenza virus vaccine intranasal - BioDiem

Drug Profile

Seasonal influenza virus vaccine intranasal - BioDiem

Alternative Names: LAIV Seasonal intranasal; Live attenuated influenza vaccine - BioDiem; Nasovac-S; SCH-900795; Seasonal influenza virus vaccine (intranasal) - BioDiem; Trivalent seasonal influenza virus vaccine - Serum Institute of India/Biodiem

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Institute of Experimental Medicine of the Russian Academy of Medical Sciences
  • Developer BioDiem; Institute of Experimental Medicine of the Russian Academy of Medical Sciences
  • Class Attenuated vaccines; Influenza virus vaccines-live; Viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Influenza virus infections

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 22 Jun 2015 No recent reports on development identified - Phase-II for Influenza virus infections (Prevention) in European Union (Intranasal)
  • 30 May 2015 Serum Institute of India enters into an agreement with Cipla for commercialisation of Seasonal influenza virus vaccine intranasal (Nasovac-S™) in India
  • 18 Feb 2014 Registered for Influenza virus infections in India (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top